



WOORI GLOBAL MARKETS ASIA LIMITED
友利投資金融有限公司

REGULATORY DISCLOSURES

FOR THE SEMI ANNUAL ENDED

30 JUNE 2022

WOORI GLOBAL MARKETS ASIA LIMITED

REGULATORY DISCLOSURES

TABLE OF CONTENTS

	Pages
1 CR1: Credit quality of exposures	1
2 CR2: Changes in defaulted loans and debt securities	2
3 CR3: Overview of recognized credit risk mitigation	3
4 CR4: Credit risk exposures and effects of recognized credit risk mitigation – BSC approach	4
5 CR5: Credit risk exposures by asset classes and by risk weights – BSC approach	5
6 CR6: Credit risk exposures by portfolio and PD ranges – for IRB approach	6
7 CR7: Effects on RWA of recognized credit derivative contracts used as recognized credit risk mitigation – for IRB approach	6
8 CR10: Specialized lending under supervisory slotting criteria approach and equities under simple risk-weight method – for IRB approach	6
9 CCR1: Analysis of counterparty default risk exposures (other than those to CCPs) by approaches	7
10 CCR2: CVA capital charge	8
11 CCR3: Counterparty default risk exposures (other than those to CCPs) by asset classes and by risk weights – BSC approach	9
12 CCR4: Counterparty default risk exposures (other than those to CCPs) by portfolio and PD range – for IRB approach	9
13 CCR5: Composition of collateral for counterparty default risk exposures (including those for contracts or transactions cleared through CCPs)	10
14 CCR6: Credit-related derivatives contracts	11
15 CCR8: Exposures to CCPs	12
16 SEC1: Securitization exposures in banking book	13
17 SEC2: Securitization exposures in trading book	14
18 SEC3: Securitization exposures in banking book and associated capital requirements – where AI acts as originator	15
19 SEC4: Securitization exposures in banking book and associated capital requirements – where AI acts as investor	16
20 MR1: Market risk under STM approach	17
21 MR3: IMM approach values for market risk exposures	17
22 MR4: Comparison of VaR estimates with gains or losses	17
23 CC1: Composition of regulatory capital	18 - 20
24 CC2: Reconciliation of regulatory capital to balance sheet	21
25 CCA: Main features of regulatory capital instruments	22
26 CCyB1: Geographical distribution of credit exposures used in countercyclical capital buffer	23
27 LR1: Summary comparison of accounting assets against leverage ratio exposure measure	24
28 LIQ2: Net Stable Funding Ratio – for category 1 institution	24

CRI: Credit quality of exposures

As at 30 June 2022		US\$						
		(a)	(b)	(c)	(d)	(e)	(f)	(g)
		Gross carrying amounts of		Allowances / impairments	Of which ECL accounting provisions for credit losses on STC approach exposures		Of which ECL accounting provisions for credit losses on IRB approach exposures	Net values (a+b-c)
		Defaulted exposures	Non-defaulted exposures		Allocated in regulatory category of specific provisions	Allocated in regulatory category of collective provisions		
1	Loans	7,998,229	260,172,459	3,217,119	-	-	-	264,953,569
2	Debt securities	-	217,428,037	-	-	-	-	217,428,037
3	Off-balance sheet exposures	-	36,815,049	-	-	-	-	36,815,049
4	Total	7,998,229	514,415,545	3,217,119	-	-	-	519,196,655

CR2: Changes in defaulted loans and debt securities

		US\$
As at 30 June 2022		(a)
		Amount
1	Defaulted loans and debt securities at end of the previous reporting period	8,278,438
2	Loans and debt securities that have defaulted since the last reporting period	-
3	Returned to non-defaulted status	-
4	Amounts written off	
5	Other changes	(280,209)
6	Defaulted loans and debt securities at end of the current reporting period	7,998,229

CR3: Overview of recognized credit risk mitigation

As at 30 June 2022		US\$				
		(a)	(b1)	(b)	(d)	(f)
		Exposures unsecured: carrying amount	Exposures to be secured	Exposures secured by recognized collateral	Exposures secured by recognized guarantees	Exposures secured by recognized credit derivative contracts
1	Loans	248,616,334	16,337,235	-	-	-
2	Debt securities	217,428,037	-	-	-	-
3	Total	466,044,371	16,337,235	-	-	-
4	Of which defaulted	7,998,229	-	-	-	-

Total exposure of loan and debt securities increased due to acquisition of new loans and debt securities, partly offset by redemption of debt securities upon maturity and repayment of loan principal during first half of 2022.

CR4: Credit risk exposures and effects of recognized credit risk mitigation – BSC approach

							US\$
As at 30 June 2022	(a)	(b)	(c)	(d)	(e)	(f)	
Exposure classes	Exposures pre-CCF and pre-CRM		Exposures post-CCF and post-CRM		RWA and RWA density		
	On-balance sheet amount	Off-balance sheet amount	On-balance sheet amount	Off-balance sheet amount	RWA	RWA density	
1 Sovereign exposures	-	-	-	-	-	0%	
2 PSE exposures	2,400,984	-	2,400,984	-	2,400,984	100%	
3 Multilateral development bank exposures	-	-	-	-	-	0%	
4 Bank exposures	56,446,255	-	56,446,255	-	19,290,938	34%	
5 Cash items	382	-	382	-	-	0%	
6 Exposures in respect of failed delivery on transactions entered into on a basis other than a delivery-versus-payment basis	-	-	-	-	-	0%	
7 Residential mortgage loans	-	-	-	-	-	0%	
8 Other exposures	456,308,144	36,815,049	456,308,144	36,815,049	466,521,438	95%	
9 Significant exposures to commercial entities	-	-	-	-	-	0%	
10 Total	515,155,765	36,815,049	515,155,765	36,815,049	488,213,360	88%	

Please refer to the disclosure template KM1 of the regulatory disclosure for the quarter ended 30 Jun 2022 of the Company for the commentary.

CR5: Credit risk exposures by asset classes and by risk weights – BSC approach

										US\$
As at 30 June 2022		(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
Exposure class	Risk weight	0%	10%	20%	35%	50%	100%	250%	Others	Total credit risk exposures amount (post CCF and post CRM)
1	Sovereign exposures	-	-	-	-	-	-	-	-	-
2	PSE exposures	-	-	-	-	-	2,400,984	-	-	2,400,984
3	Multilateral development bank exposures	-	-	-	-	-	-	-	-	-
4	Bank exposures	-	-	46,444,146	-	-	10,002,109	-	-	56,446,255
5	Cash items	382	-	-	-	-	-	-	-	382
6	Exposures in respect of failed delivery on transactions entered into on a basis other than a delivery-versus-payment basis	-	-	-	-	-	-	-	-	-
7	Residential mortgage loans	-	-	-	-	-	-	-	-	-
8	Other exposures	-	-	-	-	-	466,521,438	-	-	466,521,438
9	Significant exposures to commercial entities	-	-	-	-	-	-	-	-	-
10	Total	382	-	46,444,146	-	-	478,924,531	-	-	525,369,059

Please refer to the disclosure template KM1 of the regulatory disclosure for the quarter ended 30 Jun 2022 of the Company for the commentary.

CR6: Credit risk exposures by portfolio and PD ranges – for IRB approach

The Company does not use IRB approach to calculate the credit risk for non-securitization exposures; therefore, this disclosure template is not applicable to the Company.

CR7: Effects on RWA of recognized credit derivative contracts used as recognized credit risk mitigation – for IRB approach

The Company does not use IRB approach to calculate the credit risk for non-securitization exposures; therefore, this disclosure template is not applicable to the Company.

CR10: Specialized lending under supervisory slotting criteria approach and equities under simple risk-weight method – for IRB approach

The Company does not use IRB approach to calculate the credit risk for non-securitization exposures; therefore, this disclosure template is not applicable to the Company.

CCR1: Analysis of counterparty default risk exposures (other than those to CCPs) by approaches

As at 30 June 2022							US\$
		(a)	(b)	(c)	(d)	(e)	(f)
		Replacement cost (RC)	PFE	Effective EPE	Alpha (α) used for computing default risk exposure	Default risk exposure after CRM	RWA
1	SA-CCR (for derivative contracts)	-	-		1.4	-	-
1a	CEM (for derivative contracts)	-	-		1.4	-	-
2	IMM (CCR) approach			-	-	-	-
3	Simple Approach (for SFTs)					-	-
4	Comprehensive Approach (for SFTs)					-	-
5	VaR (for SFTs)					-	-
6	Total						-

The Company has not engaged in transaction that gave rise to Counterparty Credit Risk in the first half of 2022.

CCR2: CVA capital charge

		US\$	
As at 30 June 2022		(a)	(b)
		EAD post CRM	RWA
	Netting sets for which CVA capital charge is calculated by the advanced CVA method		
1	(i) VaR (after application of multiplication factor if applicable)		-
2	(ii) Stressed VaR (after application of multiplication factor if applicable)		-
3	Netting sets for which CVA capital charge is calculated by the standardized CVA method	-	-
4	Total	-	-

The Company has not engaged in transaction that gave rise to CVA capital charge in the first half of 2022.

CCR3: Counterparty default risk exposures (other than those to CCPs) by asset classes and by risk weights – BSC approach

As at 30 June 2022										US\$
Exposure class	Risk weight	(a)	(b)	(c)	(ca)	(d)	(f)	(ga)	(h)	(i)
		0%	10%	20%	35%	50%	100%	250%	Others	Total default risk exposure after CRM
1	Sovereign exposures	-	-	-	-	-	-	-	-	-
2	PSE exposures	-	-	-	-	-	-	-	-	-
3	Multilateral development bank exposures	-	-	-	-	-	-	-	-	-
4	Bank exposures	-	-	-	-	-	-	-	-	-
5	CIS exposures	-	-	-	-	-	-	-	-	-
6	Other exposures	-	-	-	-	-	-	-	-	-
7	Significant exposures to commercial entities	-	-	-	-	-	-	-	-	-
8	Total	-	-	-	-	-	-	-	-	-

The Company has not engaged in transaction that gave rise to Counterparty Credit Risk in the first half of 2022.

CCR4: Counterparty default risk exposures (other than those to CCPs) by portfolio and PD range – for IRB approach

The Company does not use IRB approach to calculate the counterparty default risk exposures ; therefore, this disclosure template is not applicable to the Company.

CCR5: Composition of collateral for counterparty default risk exposures (including those for contracts or transactions cleared through CCPs)

As at 30 June 2022	US\$					
	(a)	(b)	(c)	(d)	(e)	(f)
	Derivative contracts				SFTs	
	Fair value of recognized collateral received		Fair value of posted collateral		Fair value of recognized collateral received	Fair value of posted collateral
Segregated	Unsegregated	Segregated	Unsegregated			
Cash - domestic currency	-	-	-	-	-	-
Cash - other currencies	-	-	-	-	-	-
Domestic sovereign debt	-	-	-	-	-	-
Other sovereign debt	-	-	-	-	-	-
Government agency debt	-	-	-	-	-	-
Corporate bonds	-	-	-	-	-	-
Equity securities	-	-	-	-	-	-
Other collateral	-	-	-	-	-	-
Total	-	-	-	-	-	-

The Company has not engaged in derivative contracts & SFT's transaction that gave rise to Counterparty Credit Risk in the first half of 2022.

CCR6: Credit-related derivatives contracts

US\$

As at 30 June 2022	(a)	(b)
	Protection bought	Protection sold
Notional amounts		
Single-name credit default swaps	-	-
Index credit default swaps	-	-
Total return swaps	-	-
Credit-related options	-	-
Other credit-related derivative contracts	-	-
Total notional amounts	-	-
Fair values		
Positive fair value (asset)	-	-
Negative fair value (liability)	-	-

The Company has not engaged in credit-related derivatives contracts in the first half of 2022.

CCR8: Exposures to CCPs

As at 30 June 2022		US\$	
		(a) Exposure after CRM	(b) RWA
1	Exposures of the AI as clearing member or client to qualifying CCPs (total)		-
2	Default risk exposures to qualifying CCPs (excluding items disclosed in rows 7 to 10), of which:	-	-
3	(i) OTC derivative transactions	-	-
4	(ii) Exchange-traded derivative contracts	-	-
5	(iii) Securities financing transactions	-	-
6	(iv) Netting sets subject to valid cross-product netting agreements	-	-
7	Segregated initial margin	-	
8	Unsegregated initial margin	-	-
9	Funded default fund contributions	-	-
10	Unfunded default fund contributions	-	-
11	Exposures of the AI as clearing member or client to non-qualifying CCPs (total)		-
12	Default risk exposures to non-qualifying CCPs (excluding items disclosed in rows 17 to 20), of which:	-	-
13	(i) OTC derivative transactions	-	-
14	(ii) Exchange-traded derivative contracts	-	-
15	(iii) Securities financing transactions	-	-
16	(iv) Netting sets subject to valid cross-product netting agreements	-	-
17	Segregated initial margin	-	
18	Unsegregated initial margin	-	-
19	Funded default fund contributions	-	-
20	Unfunded default fund contributions	-	-

The Company has not engaged in transaction that gave rise to CCPs exposure in the first half of 2022.

SEC1: Securitization exposures in banking book

As at 30 June 2022		US\$								
		(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
		Acting as originator (excluding sponsor)			Acting as sponsor			Acting as investor		
	Traditional	Synthetic	Sub-total	Traditional	Synthetic	Sub-total	Traditional	Synthetic	Sub-total	
1	Retail (total) – of which:									
2	-	-	-	-	-	-	-	-	-	-
3	-	-	-	-	-	-	-	-	-	-
4	-	-	-	-	-	-	-	-	-	-
5	-	-	-	-	-	-	-	-	-	-
6	Wholesale (total) – of which:									
7	-	-	-	-	-	-	-	-	-	-
8	-	-	-	-	-	-	-	-	-	-
9	-	-	-	-	-	-	-	-	-	-
10	-	-	-	-	-	-	-	-	-	-
11	-	-	-	-	-	-	-	-	-	-

The Company has not engaged in securitization activities in the first half of 2022.

SEC2: Securitization exposures in trading book

		US\$								
As at 30 June 2022		(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)
		Acting as originator (excluding sponsor)			Acting as sponsor			Acting as investor		
		Traditional	Synthetic	Sub-total	Traditional	Synthetic	Sub-total	Traditional	Synthetic	Sub-total
1	Retail (total) – of which:	-	-	-	-	-	-	-	-	-
2	residential mortgage	-	-	-	-	-	-	-	-	-
3	credit card	-	-	-	-	-	-	-	-	-
4	other retail exposures	-	-	-	-	-	-	-	-	-
5	re-securitization exposures	-	-	-	-	-	-	-	-	-
6	Wholesale (total) – of which:	-	-	-	-	-	-	-	-	-
7	loans to corporates	-	-	-	-	-	-	-	-	-
8	commercial mortgage	-	-	-	-	-	-	-	-	-
9	lease and receivables	-	-	-	-	-	-	-	-	-
10	other wholesale	-	-	-	-	-	-	-	-	-
11	re-securitization exposures	-	-	-	-	-	-	-	-	-

The Company has not engaged in securitization activities in the first half of 2022.

SEC3: Securitization exposures in banking book and associated capital requirements – where AI acts as originator

US\$

As at 30 June 2022		(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(l)	(m)	(n)	(o)	(p)	(q)
		Exposure values (by RW bands)				Exposure values (by regulatory approach)				RWAs (by regulatory approach)				Capital charges after cap				
		≤20% RW	> 20% to 50% RW	> 50% to 100% RW	> 100% to < 1250% RW	1250% RW	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA
1	Total exposures	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	Traditional securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	Of which securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	Of which retail	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	Of which wholesale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	Of which re-securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	Of which senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	Of which non-senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	Synthetic securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	Of which securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	Of which retail	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	Of which wholesale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	Of which re-securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	Of which senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	Of which non-senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

The Company has not engaged in securitization activities in the first half of 2022.

SEC4: Securitization exposures in banking book and associated capital requirements – where AI acts as investor

US\$

As at 30 June 2022		(a)	(b)	(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)	(k)	(l)	(m)	(n)	(o)	(p)	(q)
		Exposure values (by RW bands)					Exposure values (by regulatory approach)				RWAs (by regulatory approach)				Capital charges after cap			
		≤20% RW	> 20% to 50% RW	> 50% to 100% RW	> 100% to < 1250% RW	1250% RW	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA	SEC-IRBA	SEC-ERBA (Incl. IAA)	SEC-SA	SEC-FBA
1	Total exposures	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
2	Traditional securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
3	Of which securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
4	Of which retail	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
5	Of which wholesale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
6	Of which re-securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
7	Of which senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
8	Of which non-senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
9	Synthetic securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
10	Of which securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
11	Of which retail	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
12	Of which wholesale	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
13	Of which re-securitization	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
14	Of which senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
15	Of which non-senior	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

The Company has not engaged in securitization activities in the first half of 2022.

MR1: Market risk under STM approach

The Company has an exemption from the calculation of market risk under section 22(1) of the Banking (Capital) Rules; therefore, this disclosure template is not applicable to the Company.

MR3: IMM approach values for market risk exposures

The Company has an exemption from the calculation of market risk under section 22(1) of the Banking (Capital) Rules; therefore, this disclosure template is not applicable to the Company.

MR4: Comparison of VaR estimates with gains or losses

The Company has an exemption from the calculation of market risk under section 22(1) of the Banking (Capital) Rules; therefore, this disclosure template is not applicable to the Company.

CC1: Composition of regulatory capital

As at 30 June 2022		(a)	(b)
		US\$	Source based on reference numbers/letters of the balance sheet under the regulatory scope of consolidation
CET1 capital: instruments and reserves			
1	Directly issued qualifying CET1 capital instruments plus any related share premium	100,000,000	[a]
2	Retained earnings	28,262,947	[b]
3	Disclosed reserves	1,001,121	[c]+[e]
4	<i>Directly issued capital subject to phase-out arrangements from CET1 (only applicable to non-joint stock companies)</i>	Not applicable	Not applicable
5	Minority interests arising from CET1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in CET1 capital of the consolidation group)	-	
6	CET1 capital before regulatory adjustments	129,264,068	
CET1 capital: regulatory deductions			
7	Valuation adjustments	-	
8	Goodwill (net of associated deferred tax liabilities)	-	
9	Other intangible assets (net of associated deferred tax liabilities)	-	
10	Deferred tax assets (net of associated deferred tax liabilities)	74,824	[b]-[j]
11	Cash flow hedge reserve	-	
12	Excess of total EL amount over total eligible provisions under the IRB approach	-	
13	Credit-enhancing interest-only strip, and any gain-on-sale and other increase in the CET1 capital arising from securitization transactions	-	
14	Gains and losses due to changes in own credit risk on fair valued liabilities	-	
15	Defined benefit pension fund net assets (net of associated deferred tax liabilities)	-	
16	Investments in own CET1 capital instruments (if not already netted off paid-in capital on reported balance sheet)	-	
17	Reciprocal cross-holdings in CET1 capital instruments	-	
18	Insignificant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	
19	Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	
20	Mortgage servicing rights (net of associated deferred tax liabilities)	Not applicable	Not applicable
21	Deferred tax assets arising from temporary differences (net of associated deferred tax liabilities)	Not applicable	Not applicable
22	Amount exceeding the 15% threshold	Not applicable	Not applicable
23	of which: significant investments in the ordinary share of financial sector entities	Not applicable	Not applicable
24	of which: mortgage servicing rights	Not applicable	Not applicable
25	of which: deferred tax assets arising from temporary differences	Not applicable	Not applicable
26	National specific regulatory adjustments applied to CET1 capital	1,081,541	
26a	Cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties)	-	
26b	Regulatory reserve for general banking risks	1,081,541	[c]
26c	Securitization exposures specified in a notice given by the MA	-	
26d	Cumulative losses below depreciated cost arising from the institution's holdings of land and buildings	-	
26e	Capital shortfall of regulated non-bank subsidiaries	-	
26f	Capital investment in a connected company which is a commercial entity (amount above 15% of the reporting institution's capital base)	-	
27	Regulatory deductions applied to CET1 capital due to insufficient AT1 capital and Tier 2 capital to cover deductions	-	
28	Total regulatory deductions to CET1 capital	1,156,365	
29	CET1 capital	128,107,703	
AT1 capital: instruments			
30	Qualifying AT1 capital instruments plus any related share premium	-	
31	of which: classified as equity under applicable accounting standards	-	
32	of which: classified as liabilities under applicable accounting standards	-	
33	<i>Capital instruments subject to phase-out arrangements from AT1 capital</i>	-	
34	AT1 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in AT1 capital of the consolidation group)	-	
35	of which: AT1 capital instruments issued by subsidiaries subject to phase-out arrangements	-	
36	AT1 capital before regulatory deductions	-	
AT1 capital: regulatory deductions			
37	Investments in own AT1 capital instruments	-	
38	Reciprocal cross-holdings in AT1 capital instruments	-	
39	Insignificant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	
40	Significant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation	-	
41	National specific regulatory adjustments applied to AT1 capital	-	
42	Regulatory deductions applied to AT1 capital due to insufficient Tier 2 capital to cover deductions	-	
43	Total regulatory deductions to AT1 capital	-	
44	AT1 capital	-	
45	Tier 1 capital (T1 = CET1 + AT1)	128,107,703	
Tier 2 capital: instruments and provisions			
46	Qualifying Tier 2 capital instruments plus any related share premium	-	
47	<i>Capital instruments subject to phase-out arrangements from Tier 2 capital</i>	-	
48	Tier 2 capital instruments issued by consolidated bank subsidiaries and held by third parties (amount allowed in Tier 2 capital of the consolidation group)	-	
49	of which: capital instruments issued by subsidiaries subject to phase-out arrangements	-	
50	Collective provisions and regulatory reserve for general banking risks eligible for inclusion in Tier 2 capital	1,604,997	[c]+[d]+[f]+[g]+[i]
51	Tier 2 capital before regulatory deductions	1,604,997	
Tier 2 capital: regulatory deductions			
52	Investments in own Tier 2 capital instruments	-	
53	Reciprocal cross-holdings in Tier 2 capital instruments	-	
54	Insignificant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	
55	Significant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (net of eligible short positions)	-	
56	National specific regulatory adjustments applied to Tier 2 capital	-	
56a	Add back of cumulative fair value gains arising from the revaluation of land and buildings (own-use and investment properties) eligible for inclusion in Tier 2 capital	-	
57	Total regulatory adjustments to Tier 2 capital	-	
58	Tier 2 capital (T2)	1,604,997	
59	Total regulatory capital (TC = T1 + T2)	129,712,700	
60	Total RWA	509,093,441	
Capital ratios (as a percentage of RWA)			
61	CET1 capital ratio	25.16%	
62	Tier 1 capital ratio	25.16%	
63	Total capital ratio	25.48%	
64	Institution-specific buffer requirement (capital conservation buffer plus countercyclical capital buffer plus higher loss absorbency requirements)	2.678%	
65	of which: capital conservation buffer requirement	2.500%	
66	of which: bank specific countercyclical capital buffer requirement	0.178%	
67	of which: higher loss absorbency requirement	0.00%	
68	CET1 (as a percentage of RWA) available after meeting minimum capital requirements	17.48%	

CCI: Composition of regulatory capital (continued)

As at 30 June 2022		(a)	(b)
		US\$	Source based on reference numbers/letters of the balance sheet under the regulatory scope of consolidation
National minima (if different from Basel 3 minimum)			
69	National CET1 minimum ratio	Not applicable	Not applicable
70	National Tier 1 minimum ratio	Not applicable	Not applicable
71	National Total capital minimum ratio	Not applicable	Not applicable
Amounts below the thresholds for deduction (before risk weighting)			
72	Insignificant capital investments in CET1, AT1 and Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation	-	
73	Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation	-	
74	Mortgage servicing rights (net of associated deferred tax liabilities)	Not applicable	Not applicable
75	Deferred tax assets arising from temporary differences (net of associated deferred tax liabilities)	Not applicable	Not applicable
Applicable caps on the inclusion of provisions in Tier 2 capital			
76	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the BSC approach, or the STC approach and SEC-ERBA, SEC-SA and SEC-FBA (prior to application of cap)	-	
77	Cap on inclusion of provisions in Tier 2 under the BSC approach, or the STC approach, and SEC-ERBA, SEC-SA and SEC-FBA	-	
78	Provisions eligible for inclusion in Tier 2 in respect of exposures subject to the IRB approach and SEC-IRBA (prior to application of cap)	-	
79	Cap for inclusion of provisions in Tier 2 under the IRB approach and SEC-IRBA	-	
Capital instruments subject to phase-out arrangements (only applicable between 1 Jan 2018 and 1 Jan 2022)			
80	<i>Current cap on CET1 capital instruments subject to phase-out arrangements</i>	Not applicable	Not applicable
81	<i>Amount excluded from CET1 due to cap (excess over cap after redemptions and maturities)</i>	Not applicable	Not applicable
82	<i>Current cap on AT1 capital instruments subject to phase-out arrangements</i>	-	
83	<i>Amount excluded from AT1 capital due to cap (excess over cap after redemptions and maturities)</i>	-	
84	<i>Current cap on Tier 2 capital instruments subject to phase-out arrangements</i>	-	
85	<i>Amount excluded from Tier 2 capital due to cap (excess over cap after redemptions and maturities)</i>	-	
<p>Points to note:</p> <p>(i) Rows with item titles in italics are rows that will be deleted after all the ineligible capital instruments have been fully phased out (i.e. from 1 January 2022 onwards).</p> <p>(ii) Shaded rows with borders indicate the following:</p> <ul style="list-style-type: none"> • a row shaded dark grey introduces a new section which provides details of a certain component of regulatory capital; • a row shaded light grey, with no thick border, represents the sum of cells in the relevant section above it; • a row shaded light grey, with a thick border, indicates a key component of regulatory capital and the regulatory capital ratios; • a row shaded yellow represents an item that is not applicable to Hong Kong. <p>(iii) The reconciliation requirements included in Template CC2 result in the decomposition of certain regulatory adjustments. For example, the disclosure template above includes the adjustment "Goodwill net of associated deferred tax liabilities". The reconciliation requirements will lead to the disclosure of both the goodwill component and the related tax liability component of this regulatory adjustment.</p> <p>(iv) Elements where a more conservative definition has been applied in the BCR relative to that set out in Basel III capital standards are disclosed below in Notes to the Template.</p>			

Please refer to the disclosure template KM1 of the regulatory disclosure for the quarter ended 30 June 2022 of the Company for the commentary.

CCI: Composition of regulatory capital (continued)

As at 30 June 2022

Notes to the Template

	Description	Hong Kong basis	Basel III basis
	Other intangible assets (net of associated deferred tax liabilities)	-	-
	<u>Explanation</u>		
9	As set out in paragraph 87 of the Basel III text issued by the Basel Committee (December 2010), mortgage servicing rights ("MSRs") may be given limited recognition in CET1 capital (and hence be excluded from deduction from CET1 capital up to the specified threshold). In Hong Kong, an AI is required to follow the accounting treatment of including MSRs as part of intangible assets reported in the AI's financial statements and to deduct MSRs in full from CET1 capital. Therefore, the amount to be deducted as reported in row 9 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 9 (i.e. the amount reported under the "Hong Kong basis") adjusted by reducing the amount of MSRs to be deducted to the extent not in excess of the 10% threshold set for MSRs and the aggregate 15% threshold set for MSRs, DTAs arising from temporary differences and significant investments in CET1 capital instruments issued by financial sector entities (excluding those that are loans, facilities or other credit exposures to connected companies) under Basel III.		
	Deferred tax assets (net of associated deferred tax liabilities)	74,824	74,824
	<u>Explanation</u>		
10	As set out in paragraphs 69 and 87 of the Basel III text issued by the Basel Committee (December 2010), DTAs of the bank to be realized are to be deducted, whereas DTAs which relate to temporary differences may be given limited recognition in CET1 capital (and hence be excluded from deduction from CET1 capital up to the specified threshold). In Hong Kong, an AI is required to deduct all DTAs in full, irrespective of their origin, from CET1 capital. Therefore, the amount to be deducted as reported in row 10 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 10 (i.e. the amount reported under the "Hong Kong basis") adjusted by reducing the amount of DTAs to be deducted which relate to temporary differences to the extent not in excess of the 10% threshold set for DTAs arising from temporary differences and the aggregate 15% threshold set for MSRs, DTAs arising from temporary differences and significant investments in CET1 capital instruments issued by financial sector entities (excluding those that are loans, facilities or other credit exposures to connected companies) under Basel III.		
	Insignificant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	-
	<u>Explanation</u>		
18	For the purpose of determining the total amount of insignificant capital investments in CET1 capital instruments issued by financial sector entities, an AI is required to aggregate any amount of loans, facilities or other credit exposures provided by it to any of its connected companies, where the connected company is a financial sector entity, as if such loans, facilities or other credit exposures were direct holdings, indirect holdings or synthetic holdings of the AI in the capital instruments of the financial sector entity, except where the AI demonstrates to the satisfaction of the MA that any such loan was made, any such facility was granted, or any such other credit exposure was incurred, in the ordinary course of the AI's business. Therefore, the amount to be deducted as reported in row 18 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 18 (i.e. the amount reported under the "Hong Kong basis") adjusted by excluding the aggregate amount of loans, facilities or other credit exposures to the AI's connected companies which were subject to deduction under the Hong Kong approach.		
	Significant capital investments in CET1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	-
	<u>Explanation</u>		
19	For the purpose of determining the total amount of significant capital investments in CET1 capital instruments issued by financial sector entities, an AI is required to aggregate any amount of loans, facilities or other credit exposures provided by it to any of its connected companies, where the connected company is a financial sector entity, as if such loans, facilities or other credit exposures were direct holdings, indirect holdings or synthetic holdings of the AI in the capital instruments of the financial sector entity, except where the AI demonstrates to the satisfaction of the MA that any such loan was made, any such facility was granted, or any such other credit exposure was incurred, in the ordinary course of the AI's business. Therefore, the amount to be deducted as reported in row 19 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 19 (i.e. the amount reported under the "Hong Kong basis") adjusted by excluding the aggregate amount of loans, facilities or other credit exposures to the AI's connected companies which were subject to deduction under the Hong Kong approach.		
	Insignificant capital investments in AT1 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	-
	<u>Explanation</u>		
39	The effect of treating loans, facilities or other credit exposures to connected companies which are financial sector entities as CET1 capital instruments for the purpose of considering deductions to be made in calculating the capital base (see note re row 18 to the template above) will mean the headroom within the threshold available for the exemption from capital deduction of other insignificant capital investments in AT1 capital instruments may be smaller. Therefore, the amount to be deducted as reported in row 39 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 39 (i.e. the amount reported under the "Hong Kong basis") adjusted by excluding the aggregate amount of loans, facilities or other credit exposures to the AI's connected companies which were subject to deduction under the Hong Kong approach.		
	Insignificant capital investments in Tier 2 capital instruments issued by financial sector entities that are outside the scope of regulatory consolidation (amount above 10% threshold)	-	-
	<u>Explanation</u>		
54	The effect of treating loans, facilities or other credit exposures to connected companies which are financial sector entities as CET1 capital instruments for the purpose of considering deductions to be made in calculating the capital base (see note re row 18 to the template above) will mean the headroom within the threshold available for the exemption from capital deduction of other insignificant capital investments in Tier 2 capital instruments may be smaller. Therefore, the amount to be deducted as reported in row 54 may be greater than that required under Basel III. The amount reported under the column "Basel III basis" in this box represents the amount reported in row 54 (i.e. the amount reported under the "Hong Kong basis") adjusted by excluding the aggregate amount of loans, facilities or other credit exposures to the AI's connected companies which were subject to deduction under the Hong Kong approach.		
Remarks:			
The amount of the 10% threshold mentioned above is calculated based on the amount of CET1 capital determined in accordance with the deduction methods set out in BCR Schedule 4F. The 15% threshold is referring to paragraph 88 of the Basel III text issued by the Basel Committee (December 2010) and has no effect to the Hong Kong regime.			

CC2: Reconciliation of regulatory capital to balance sheet

As at 30 June 2022	(a) / (b)	(c)
	Balance sheet as in published financial statements / Under regulatory scope of consolidation	Reference
	US\$	
Assets		
Cash	382	
Balances with banks and other financial institutions	7,362,504	
Placements with banks	12,697,046	
Of which: impairment loss - collective	19,724	[f]
Loans and advances to customers	264,953,569	
Of which: impairment loss - collective	404,861	[g]
Of which: impairment loss - specific	2,812,258	
Debt investments at fair value through other comprehensive income	217,428,037	
Equity investments at fair value through profit or loss	9,967,581	
Property and equipment	55,615	
Right-of-use assets	1,365,615	
Deferred tax assets	74,824	[h]
Other assets	296,671	
Tax receivable	-	
Total assets	514,201,844	
Liabilities		
Loan due to banks and other financial institutions	381,258,032	
Other payables and accruals	873,251	
Of which: impairment loss - collective	40,567	[i]
Lease liabilities	1,360,655	
Tax payable	1,387,534	
Deferred tax liabilities	-	[j]
Total liabilities	384,879,472	
Shareholders' equity		
Share capital	100,000,000	[a]
Reserves	29,322,372	
Of which: retained profits	28,262,947	[b]
Of which: regulatory reserve	1,081,541	[c]
Of which: impairment loss - collective	58,304	[d]
Of which: Fair value reserve	(80,420)	[e]
Total shareholders' equity	129,322,372	

CCA: Main features of regulatory capital instruments

As at 30 June 2022		(a)
		Quantitative / qualitative information
1	Issuer	WOORI GLOBAL MARKETS ASIA LIMITED
2	Unique identifier (e.g. CUSIP, ISIN or Bloomberg identifier for private placement)	NOT APPLICABLE
3	Governing law(s) of the instrument	HONG KONG
	<i>Regulatory treatment</i>	
4	Transitional Basel III rules	CET1
5	Post-transitional Basel III rules	CET1
6	Eligible at solo / group / solo and group	SOLO
7	Instrument type (types to be specified by each jurisdiction)	ORDINARY SHARES
8	Amount recognised in regulatory capital (currency in millions, as of most recent reporting date)	HKD780 (USD100)
9	Par value of instrument	HKD10 PER SHARE, 78,000,000 SHARES
10	Accounting classification	SHAREHOLDERS EQUITY
11	Original date of issuance	NOT APPLICABLE
12	Perpetual or dated	PERPETUAL
13	Original maturity date	NOT APPLICABLE
14	Issuer call subject to prior supervisory approval	NO
15	Optional call date, contingent call dates and redemption amount	NOT APPLICABLE
16	Subsequent call dates, if applicable	NOT APPLICABLE
	<i>Coupons / dividends</i>	
17	Fixed or floating dividend / coupon	FLOATING
18	Coupon rate and any related index	NOT APPLICABLE
19	Existence of a dividend stopper	NO
20	Fully discretionary, partially discretionary or mandatory	FULLY DISCRETIONARY
21	Existence of step-up or other incentive to redeem	NO
22	Non-cumulative or cumulative	NONCUMULATIVE
23	Convertible or non-convertible	NON-CONVERTIBLE
24	If convertible, conversion trigger(s)	NOT APPLICABLE
25	If convertible, fully or partially	NOT APPLICABLE
26	If convertible, conversion rate	NOT APPLICABLE
27	If convertible, mandatory or optional conversion	NOT APPLICABLE
28	If convertible, specify instrument type convertible into	NOT APPLICABLE
29	If convertible, specify issuer of instrument it converts into	NOT APPLICABLE
30	Write-down feature	NO
31	If write-down, write-down trigger(s)	NOT APPLICABLE
32	If write-down, full or partial	NOT APPLICABLE
33	If write-down, permanent or temporary	NOT APPLICABLE
34	If temporary write-down, description of write-up mechanism	NOT APPLICABLE
35	Position in subordination hierarchy in liquidation (specify instrument type immediately senior to instrument in the insolvency creditor hierarchy of the legal entity concerned).	NOT APPLICABLE
36	Non-compliant transitioned features	NO
37	If yes, specify non-compliant features	NOT APPLICABLE
<p><i>Points to note:</i></p> <p>(i) An AI should report the main features of each outstanding regulatory capital instrument. For any item that is not applicable for a particular capital instrument, "NA" should be entered.</p> <p>(ii) In order to provide a "main features report" that summarises all of the regulatory capital instruments of the banking group, an AI should report each instrument, including ordinary shares, in a separate column of this template (by adding column (b), column (c) and so on).</p> <p>(iii) An AI should select one of the standard options in the list as the input for a particular cell, where relevant. The following table provides a more detailed explanation of reporting requirements for each of the cells, and, where relevant, the list of standard options from which the AI should select as the input for a particular cell.</p>		

CCyB1: Geographical distribution of credit exposures used in countercyclical capital buffer (“CCyB”)

As at 30 June 2022

					US\$
		(a)	(c)	(d)	(e)
	Geographical breakdown by Jurisdiction (J)	Applicable JCCyB ratio in effect (%)	RWA used in computation of CCyB ratio (US\$)	AI-specific CCyB ratio (%)	CCyB amount
1	Hong Kong SAR	1.000%	393,220		
N+1	Sum		393,220		
N+2	Total		2,208,998	0.178%	906,186
<i>Point to note:</i>					
<i>(i) no disclosure is required for items shaded in dark grey (i.e. column (d) and (e) in rows 3 to N+1, cells N+1/a and N+2/a).</i>					

The table above sets out the Company’s CCyB ratio, the risk weighted amounts (“RWA”) of its private sector credit exposures by jurisdiction and the Jurisdictional CCyB (“JCCyB”) ratios as announced by the relevant jurisdictions which are used for calculating the Company’s CCyB ratio. The attribution of the Company’s private sector credit exposures by jurisdiction is determined on an ultimate risk basis pursuant to the HKMA Supervisory Policy Manual module CA-B-3 “Counterparty Capital Buffer (CCyB) – Geographic Allocation of Private Sector Credit Exposures”, considering factors such as country of residence and location of collateral, as applicable.

LRI: Summary comparison of accounting assets against leverage ratio (“LR”) exposure measure

As at 30 June 2022

		(a)
	Item	Value under the LR framework (US\$)
1	Total consolidated assets as per published financial statements	514,201,844
2	Adjustment for investments in banking, financial, insurance or commercial entities that are consolidated for accounting purposes but outside the scope of regulatory consolidation	-
2a	Adjustment for securitised exposures that meet the operational requirements for the recognition of risk transference	-
3	Adjustment for fiduciary assets recognised on the balance sheet pursuant to the applicable accounting standard but excluded from the LR exposure measure	-
3a	Adjustments for eligible cash pooling transactions	
4	Adjustments for derivative contracts	-
5	Adjustment for SFTs (i.e. repos and similar secured lending)	-
6	Adjustment for off-balance sheet (“OBS”) items (i.e. conversion to credit equivalent amounts of OBS exposures)	10,213,294
6a	Adjustment for prudent valuation adjustments and specific and collective provisions that are allowed to be excluded from exposure measure	-
7	Other adjustments	3,859,083
8	Leverage ratio exposure measure	528,274,221

The difference between the total on balance sheet exposures as reported in the financial statements and on-balance sheet exposures in row 1 of Template LR2 is mainly due to the reason that loans and advances to customers and placements with banks are reported as net amount after impairment in the financial statements while they are reported in their gross amount in row 1 of Template LR2, and also the difference in recognizing Loans and advances to customers at amortized cost using effective interest rate in the financial statement while gross amount of Loans and advances to customers was used in row 1 of Template LR2. For detail of the Template LR2, please refer to the regulatory disclosure for the quarter ended 30 June 2022 of the Company.

LIQ2: Net Stable Funding Ratio – for category 1 institution

The Company is not designated by the Monetary Authority as a category 1 institution; therefore, this disclosure template is not applicable to the Company.